Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — Shareholder Meeting (October 2014)
29 slides from Monash Ivf's shareholder meeting presentation, Oct 28, 2014
Slide 1: Annual General Meeting
For personal use only ANNUAL GENERAL MEETING
Slide 2: Chairman's Address – Richard Davis
For personal use only ANNUAL GENERAL MEETING CHAIRMAN’S ADDRESS – RICHARD DAVIS 28 OCTOBER 2014
Slide 3: Chairman's Address: Historic year. Strong performance.
CHAIRMAN’S ADDRESS For personal use only Historic year. Strong performance. Monash IVF Group (ASX: MVF) listed on the Australian Securities Exchange June 2014 Delivered strong financial results for FY2014 Exceeded all pro-forma Prospectus forecasts Full year pro-forma Net Profit after Tax of $22.6 m
Slide 4: Chairman's Address: Historic year. Strong performance.
CHAIRMAN’S ADDRESS For personal use only Historic year. Strong performance. Heritage of scientific excellence drives our commitment to enhancing and expanding technological capabilities and research into patient focused services Monash IVF Research and Education Foundation Our research and postgradu
Slide 5: CEO Presentation - James Thiedeman
For personal use only ANNUAL GENERAL MEETING CEO PRESENTATION - JAMES THIEDEMAN 28 OCTOBER 2014
Slide 6: Disclaimer
DISCLAIMER For personal use only The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The info
Slide 7: Overview of Monash IVF Group
OVERVIEW OF MONASH IVF GROUP For personal use only Monash Group is a market leader in the growing field of fertility services… Core Assisted Reproductive Services Diagnostic and ancillary services Ultrasound Australia Malaysia Range of treatments and techniques to assist Diagnostic and genetic testi
Slide 8: Monash Group's Key Pillars
MONASH GROUP’S KEY PILLARS For personal use only 1 1 Leader in science and innovation •Provide patients with the highest success rates and effective treatment •Continue to invest in advances in Pre Implantation Screening (PGS) technology 2 Industry leader in Australia with significant scale advantag
Slide 9: FY2014 Operational Highlights
FY2014 OPERATIONAL HIGHLIGHTS For personal use only Delivering on key pillars Leader in science and innovation Patient success – FY2014 success rate of 32% vs industry average of 25%(1) Diagnostic and ancillary services – continued strong patient demand for PGS and NIPT offering Industry leader in A
Slide 10: FY2014 Financial Highlights
FY2014 FINANCIAL HIGHLIGHTS For personal use only Record revenue and earnings growth in FY2014 and ahead of prospectus forecasts Vs. Vs. Pro Forma FY2014 Pro Forma Pro Forma FY2013 Forecast Pro Forma Actual Actual Pro Forma (Prospectus) Forecast Actual (Prospectus) $ million FY2014 FY2013 FY2014 $’M
Slide 11: FY2014 Financial Highlights
FY2014 FINANCIAL HIGHLIGHTS For personal use only Record revenue growth in FY2014 and ahead of prospectus forecast Statutory Statutory Statutory Actual Prospectus Actual $ million FY2014 FY2014 FY2013 $’M $’M $’M Revenue 114.0 112.1 96.6 EBITDA 24.5 25.2 36.7 EBIT 21.6 22.4 32.1 NPAT 4.9 4.9 (12.7)
Slide 12: FY2014 Result Detail
For personal use only FY2014 RESULT DETAIL
Slide 13: Patient Treatment Growth
PATIENT TREATMENT GROWTH For personal use only Strong Patient Treatment growth reflecting continued steady organic growth and initial contribution of acquisitions Patient Treatments Year-on-Year Analysis Prospectus • Australian business up 9.5% FY2014 FY2013 Change FY2014 – Organic growth of 4.2% (e
Slide 14: Summary Income Statement
SUMMARY INCOME STATEMENT For personal use only Strong revenue and earnings growth Year-on-Year Analysis Pro Forma Income Statement • Revenue up 18.4% driven by: Prospectus $ million FY2014 FY2013 Change FY2014 – 13.6% growth in Patient Treatments (combination of organic growth, Total Revenue 114.0 9
Slide 15: Strategy, Trading Update and Outlook
For personal use only STRATEGY, TRADING UPDATE AND OUTLOOK
Slide 16: Strategy
STRATEGY For personal use only Focused strategy consistent with Monash Group’s key pillars Science, • Continue to develop industry leading science and technology technology & • Deliver patients with clinically superior services and increase market penetration patient success • Promote Monash Group’s
Slide 17: Q1 FY2015 Trading Update
Q1 FY2015 TRADING UPDATE For personal use only Monash has increased share in its key markets(1) in July & August FY2015 Share in key Monash markets(1) increased to 39.8% from 39.1% (pcp)(2) Strong growth in overall Monash New Patient Registrations/Conversions up 11% on pcp Monash lower intervention
Slide 18: Q1 FY2015 Trading Update
Q1 FY2015 TRADING UPDATE For personal use only Next Generation Fertility performing above expectations Strong growth in uptake of PGS/PGD across Monash clinic network PGS volume growth up 12% on pcp Further momentum expected over the balance of FY2015 Two (2) additional Specialists added to the Mona
Slide 19: Q1 FY2015 Trading Update
Q1 FY2015 TRADING UPDATE For personal use only Q1 FY2015 result impacted by Contraction in total ARS market in Australia in July & August FY2015 with total Patient Treatments in key Monash markets(1) falling 3.7% Prospectus forecast assumed Patient Treatment market growth in Australia of ~4%(2) As i
Slide 20: Q1 FY2015 Trading Update
Q1 FY2015 TRADING UPDATE For personal use only Q1 FY2015 result impacted by Patient Treatment mix shift Continued shift in Patient Treatment mix from fresh to frozen cycles due to improved Frozen Embryo Transfer (FET) pregnancy success rates has impacted revenue in Q1 FY2015 Fresh cycle mix in Q1 FY
Slide 21: FY2015 Outlook
FY2015 OUTLOOK For personal use only Q1 FY2015 trading conditions impacted Revenue and EBITDA by $3.1 million and $2.6 million respectively Notwithstanding challenging conditions, the current outlook for Monash in FY2015 remains strong Strength in Q1 New Patient Registrations/Conversions (up on pcp
Slide 22: Monash IVF Group - Life Starts Here
For personal use only MONASH IVF GROUP - LIFE STARTS HERE 22
Slide 23: Business of the AGM
For personal use only BUSINESS OF THE AGM
Slide 24: Resolution One: Financial, Director's and Auditor's Reports
MONASH IVF GROUP For personal use only Resolution One: To receive and consider the Financial Report, Director’s Report and Auditor’s Report for the year ended 30 June 2014. There is no requirement for a formal resolution on this item. Shareholders can ask questions of the Board and Auditor with rega
Slide 25: Resolution Two: Remuneration Report
MONASH IVF GROUP For personal use only Resolution Two: That the Remuneration Report, which forms part of the Director’s Report for the year ended 30 June 2014, be adopted. Proxy voting: Votes in favour of the resolution - 86,160,015 Votes against the resolution – 18,072,515 Open votes – 3,833,930 Ab
Slide 26: Resolution Three: Appointment of Auditor
MONASH IVF GROUP For personal use only Resolution Three: That KPMG, having been nominated by a member of the Company, in accordance with Section 328B of the Corporations Act and having given its consent to act as Auditor, in accordance with the Corporations Act, be appointed as the Auditor of the Co
Slide 27: Resolution Four A: Re-election of Richard Davis
MONASH IVF GROUP For personal use only Resolution Four A: That Mr Richard Davis, who retires in accordance with the Company’s Constitution, be re-elected as a director of the Company. Proxy voting: Votes in favour of the resolution – 109,570,222 Votes against the resolution – 14,181 Open votes – 182
Slide 28: Resolution Four B: Re-election of Dr Richard Henshaw
MONASH IVF GROUP For personal use only Resolution Four B: That Dr Richard Henshaw, who retires in accordance with the Company’s Constitution, be re-elected as a director of the Company. Proxy voting: Votes in favour of the resolution – 106,775,443 Votes against the resolution – 2,795,460 Open votes
Slide 29: Thank You for Attending
For personal use only THANK YOU FOR ATTENDING
Monash IVF Group — Shareholder Meeting (October 2014) on 6ix